Kerna Ventures
Overview
Kerna Ventures is a London-based venture capital firm established in 2022. The firm specializes in early-stage investments in advanced therapeutic platform technologies, focusing on areas such as genome engineering, cell reprogramming, and computational biology. Kerna Ventures primarily invests in seed through Series A stages, with ticket sizes ranging from $500,000 to $5 million. The firm's portfolio includes companies like GenEdit, Axent, Nodal Therapeutics, Renewal Bio, Geneditor, Pasqal, and Proteinea. Kerna Ventures is committed to supporting innovative startups that aim to revolutionize healthcare through cutting-edge scientific advancements.
Investment Focus
- Innovative technology startups
- Advanced therapeutic platform technologies
- Seed through Series A stages
- Ticket sizes between $500,000 and $5 million
Portfolio Companies
Reach Kerna Ventures directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Kerna Ventures
What sectors does Kerna Ventures invest in?
Kerna Ventures invests in Healthcare, Artificial Intelligence, Digital Health, Pharmaceuticals, Medical Devices and Diagnostics, and is based in United Kingdom. Kerna Ventures is listed as a venture capital in the ConnectSafely investor database.
What stage does Kerna Ventures invest at?
Kerna Ventures backs companies at Seed, Early Stage, Series A, Series B, Growth and Late Stage, writing cheques of 500K - 5M.
Which regions does Kerna Ventures invest in?
Kerna Ventures invests across United States, United Kingdom, Germany, France, Italy and Denmark.
What companies has Kerna Ventures invested in?
Kerna Ventures's portfolio includes PASQAL, GenEdit, Axent, Nodal Therapeutics, Renewal Bio, Geneditor and Proteinea.
How do I contact Kerna Ventures?
Kerna Ventures's contact details — including LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of the team.
Last updated · Source: ConnectSafely investor database
